# US 2017/0281650 A1 · Use of dihydrocholesterol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281650 A1
- Document ID: US20170281650A1
- Status: Published application
- Kind: A1
- Application number: 15/508,278
- Filed: 2014-09-02
- Published: 2017-10-05
- Earliest claimed: 2014-09-02
- Assignees: Nestec S.A.
- Applicants: Nestec S.A.
- Inventors: Lei Guan; Youyou Zhao; Junkuan Wang
- Web page: https://patentgrep.com/patent/US20170281650A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/60: involving cholesterol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The use of dihydrocholesterol (DHC) in low doses of up to 50 mg per kg of body weight to treat or prevention excess weight or obesity and/or hyperlipidemia, and/or a disorders associated with any of the foregoing, and a composition comprising DHC.

## Claims

### Claim 1

A method for treating and/or preventing excess weight or obesity and/or hyperlipidemia, and/or a disorder associated with any of the foregoing comprising administering dihydrocholesterol at a dose of up to 50 mg per kg of body weight to an individual in need of same.

### Claim 2 (depends on 1)

Method according to claim 1 wherein, the dihydrocholesterol is used at a dose of up to 40 mg per kg of body weight.

### Claim 3 (depends on 1)

Method according to claim 1 wherein, the disorder associated with excess weight or obesity and/or hyperlipidemia is selected from the group consisting of; lipoprotein dysregulation, hyperlipidemia related cardio-cerebro-vascular diseases including coronary heart disease, angina, myocardial infarction, atherosclerosis, coronary artery disease, stroke, claudication, peripheral vascular disease, metabolic diseases such as obesity, fatty liver disease, type II diabetes and combinations thereof.

### Claim 4 (depends on 1)

Method according to claim 1 wherein hyperlipidemia is selected from the group consisting of hypercholesterolemia, hypertriglyceridemia, and combinations thereof.

### Claim 5 (depends on 1)

Method according to claim 1 wherein the individual is selected from the group consisting of: human, cat, and dog.

### Claim 6 (depends on 1)

Method according to claim 1 wherein the DHC is administered enterally.

### Claim 7 (depends on 1)

Method according to claim 1 wherein the DHC is used in conjunction with a diet and/or exercise program.

### Claim 8 (depends on 5)

Method according to claim 5 wherein the individual is elderly.

### Claim 9 (depends on 1)

Method according to claim 1 wherein said DHC is used in the form of a composition selected from the group consisting of: a nutritional product, a food product, a functional food product, a healthy ageing product, a dairy product, a nutritional supplement, a pharmaceutical formulation, a beverage product, a diet, and a pet food product.

### Claim 10

A composition comprising dihydrocholesterol at a concentration of 0.01 to 0.4% by weight.

### Claim 11 (depends on 10)

A composition according to claim 10 selected from the group consisting of: a nutritional product, a food product, a functional food product, a healthy ageing product, a dairy product, a nutritional supplement, a pharmaceutical formulation, a beverage product, a diet, and a pet food product.

### Claim 12 (depends on 11)

A composition according to claim 11 wherein the compositions is a product selected from the group consisting of: a low-fat milk, a fat-free milk, a milk product, and a protein powder.

### Claim at position 13

13-14. (canceled)

### Claim 15

A kit for providing dihydrocholesterol in a low dose up to 50 mg per kg of body weight, the kit comprising:
DHC or a composition comprising DHC; and
a label indicating dosage requirements for said DHC, or the composition, so that the dose equates or corresponds to a dose of DHC of up to 50 mg per kg of body weight.
